About this Research Topic
** INVITATION ONLY ** This flagship Research Topic is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA).
Advancements in drug development have accelerated the innovation of therapeutic strategies in the field of oncology. One promising approach gaining significant attention is the utilization of bi-specific antibodies. These antibodies are uniquely engineered to simultaneously target two distinct antigens - by binding to tumor-specific antigens and immune cell receptors (T-cell engagers), bi-specific antibodies facilitate the activation of immune responses against cancer cells, leading to enhanced precision and efficacy of treatment.
The versatility of bi-specific antibodies offer many advantages over traditional monoclonal antibodies, such as increased specificity and potency, enabling the destruction of cancer cells while sparing healthy tissues, thereby minimizing side effects commonly associated with traditional chemotherapy. This breakthrough technology has the potential to revolutionize oncology treatment and improve patient outcomes.
Numerous bi-specific antibody therapies are currently being investigated in preclinical and clinical trials, and several of these have already received regulatory approval for the treatment of hematological malignancies, demonstrating their clinical efficacy and safety. With ongoing research and development, the application of bi-specific antibodies in solid tumors is also being explored, offering an exciting prospect for expanding treatment options in a broader range of cancer types. Collectively, the advancements in bi-specific antibody therapy hold promise for transforming the treatment landscape for oncology patients, paving the way for more targeted and effective interventions in the fight against cancer.
This research topic delves into the design, development and mechanisms of action of bi- specific antibodies, shedding light on successes, challenges and future directions in the development and clinical application of bi-specific antibodies. We welcome submissions of Original Research, Reviews, Mini Reviews, Methods, and Clinical Trials. Authors wishing to contribute a viewpoint or interpretation of recent findings are encouraged to submit an Opinion or Perspective piece.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Advancements in drug development have accelerated the innovation of therapeutic strategies in the field of oncology. One promising approach gaining significant attention is the utilization of bi-specific antibodies. These antibodies are uniquely engineered to simultaneously target two distinct antigens - by binding to tumor-specific antigens and immune cell receptors (T-cell engagers), bi-specific antibodies facilitate the activation of immune responses against cancer cells, leading to enhanced precision and efficacy of treatment.
The versatility of bi-specific antibodies offer many advantages over traditional monoclonal antibodies, such as increased specificity and potency, enabling the destruction of cancer cells while sparing healthy tissues, thereby minimizing side effects commonly associated with traditional chemotherapy. This breakthrough technology has the potential to revolutionize oncology treatment and improve patient outcomes.
Numerous bi-specific antibody therapies are currently being investigated in preclinical and clinical trials, and several of these have already received regulatory approval for the treatment of hematological malignancies, demonstrating their clinical efficacy and safety. With ongoing research and development, the application of bi-specific antibodies in solid tumors is also being explored, offering an exciting prospect for expanding treatment options in a broader range of cancer types. Collectively, the advancements in bi-specific antibody therapy hold promise for transforming the treatment landscape for oncology patients, paving the way for more targeted and effective interventions in the fight against cancer.
This research topic delves into the design, development and mechanisms of action of bi- specific antibodies, shedding light on successes, challenges and future directions in the development and clinical application of bi-specific antibodies. We welcome submissions of Original Research, Reviews, Mini Reviews, Methods, and Clinical Trials. Authors wishing to contribute a viewpoint or interpretation of recent findings are encouraged to submit an Opinion or Perspective piece.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: bi-specific antibody, drug development, mechanisms of action, cancer therapy, clinical application
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
